ID

14153

Descripción

Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02462265

Link

https://clinicaltrials.gov/show/NCT02462265

Palabras clave

  1. 1/4/16 1/4/16 -
Subido en

1 de abril de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Acute Myeloid Leukemia NCT02462265

Eligibility Acute Myeloid Leukemia NCT02462265

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients is diagnosed as aml or all
Descripción

aml or all

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023467
UMLS CUI [2]
C0023449
relapse defined as the presence of disease after the achievement of complete remission(cr). refractory disease is defined as progression from or no response while treated with a previous line chemotherapy regimen, or progression within 30 days of last bone marrow assessment.
Descripción

Relapse AML

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2367456
male or female ≥ 18 years of age
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
minimal performance status (ecog 0, ≤2)
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
patients must have a measurable disease by bone marrow blast counts of > 5 % of nucleated cells.
Descripción

bone marrow blast count

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2697913
written informed consent
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
adequate hepatic function (lfts up to x4 the normal limits), renal function calculated creatinine clearance (crcl) for adverse effects of >30)
Descripción

Liver and renal function

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C0232804
ability to swallow the medications.
Descripción

Ability to swallow tablet

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3838726
females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 6 weeks after treatment discontinuation.
Descripción

Contraceptive methods

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0700589
females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy.
Descripción

Pregnancy test negative

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0427780
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
active infectious disease uncontrolled by antibiotics.
Descripción

Communicable Diseases

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009450
partially treated induction patients (i.e. day 14 non responding patients).
Descripción

Induction patients

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0205263
Inability to receive high dose salvage chemotherapy.
Descripción

Chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3665472
patient with known positive hiv serology at screening.
Descripción

HIV Seropositivity

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019699
female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study.
Descripción

Breastfeeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1623040
UMLS CUI [2]
C0240802
evidence of ongoing cardiac dysrhythmias of nci common toxicity criteria for adverse effects (ctcae ) version 3.0 grade 2.
Descripción

Cardiac Arrhythmia

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0003811
pre-existing malabsorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption.
Descripción

Malabsorption Syndrome

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0024523
UMLS CUI [2]
C0022104
mental disorders
Descripción

mental disorders

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0004936
inability to give written informed consent
Descripción

No written consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0811746

Similar models

Eligibility Acute Myeloid Leukemia NCT02462265

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
aml or all
Item
patients is diagnosed as aml or all
boolean
C0023467 (UMLS CUI [1])
C0023449 (UMLS CUI [2])
Relapse AML
Item
relapse defined as the presence of disease after the achievement of complete remission(cr). refractory disease is defined as progression from or no response while treated with a previous line chemotherapy regimen, or progression within 30 days of last bone marrow assessment.
boolean
C2367456 (UMLS CUI [1])
Age
Item
male or female ≥ 18 years of age
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
minimal performance status (ecog 0, ≤2)
boolean
C1520224 (UMLS CUI [1])
bone marrow blast count
Item
patients must have a measurable disease by bone marrow blast counts of > 5 % of nucleated cells.
boolean
C2697913 (UMLS CUI [1])
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Liver and renal function
Item
adequate hepatic function (lfts up to x4 the normal limits), renal function calculated creatinine clearance (crcl) for adverse effects of >30)
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
Ability to swallow tablet
Item
ability to swallow the medications.
boolean
C3838726 (UMLS CUI [1])
Contraceptive methods
Item
females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 6 weeks after treatment discontinuation.
boolean
C0700589 (UMLS CUI [1])
Pregnancy test negative
Item
females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy.
boolean
C0427780 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Communicable Diseases
Item
active infectious disease uncontrolled by antibiotics.
boolean
C0009450 (UMLS CUI [1])
Induction patients
Item
partially treated induction patients (i.e. day 14 non responding patients).
boolean
C0205263 (UMLS CUI [1])
Chemotherapy
Item
Inability to receive high dose salvage chemotherapy.
boolean
C3665472 (UMLS CUI [1])
HIV Seropositivity
Item
patient with known positive hiv serology at screening.
boolean
C0019699 (UMLS CUI [1])
Breastfeeding
Item
female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study.
boolean
C1623040 (UMLS CUI [1])
C0240802 (UMLS CUI [2])
Cardiac Arrhythmia
Item
evidence of ongoing cardiac dysrhythmias of nci common toxicity criteria for adverse effects (ctcae ) version 3.0 grade 2.
boolean
C0003811 (UMLS CUI [1])
Malabsorption Syndrome
Item
pre-existing malabsorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption.
boolean
C0024523 (UMLS CUI [1])
C0022104 (UMLS CUI [2])
mental disorders
Item
mental disorders
boolean
C0004936 (UMLS CUI [1])
No written consent
Item
inability to give written informed consent
boolean
C0811746 (UMLS CUI [1])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial